 |
PDBsum entry 3mj5
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Viral protein
|
PDB id
|
|
|
|
3mj5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Viral protein
|
 |
|
Title:
|
 |
Severe acute respiratory syndrome-coronavirus papain-like protease inhibitors: design, synthesis, protein-ligand x-ray structure and biological evaluation
|
|
Structure:
|
 |
Replicase polyprotein 1a. Chain: a, b. Fragment: sars polyprotein residues 1544-1855. Synonym: pp1a, orf1a polyprotein, non-structural protein 1, nsp1, leader protein, non-structural protein 2, nsp2, p65 homolog, non- structural protein 3, nsp3, papain-like proteinase, pl-pro, pl2-pro, non-structural protein 4, nsp4, 3c-like proteinase, 3cl-pro, 3clp, nsp5, non-structural protein 6, nsp6, non-structural protein 7, nsp7, non-structural protein 8, nsp8, non-structural protein 9, nsp9, non-
|
|
Source:
|
 |
Sars coronavirus. Sars-cov. Organism_taxid: 227859. Strain: urbani. Gene: 1a, orf1 (nsp3) residues 1544-1855. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
2.63Å
|
R-factor:
|
0.211
|
R-free:
|
0.248
|
|
|
Authors:
|
 |
A.D.Mesecar,K.M.Ratia,S.D.Pegan
|
|
Key ref:
|
 |
A.K.Ghosh
et al.
(2010).
Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
J Med Chem,
53,
4968-4979.
PubMed id:
|
 |
|
Date:
|
 |
|
12-Apr-10
|
Release date:
|
30-Jun-10
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, B:
E.C.2.7.7.50
- mRNA guanylyltransferase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 5'-end diphospho-ribonucleoside in mRNA + GTP + H+ = a 5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate
|
 |
 |
 |
 |
 |
5'-end diphospho-ribonucleoside in mRNA
|
+
|
GTP
|
+
|
H(+)
|
=
|
5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chains A, B:
E.C.3.4.19.12
- ubiquitinyl hydrolase 1.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Thiol-dependent hydrolysis of ester, thiolester, amide, peptide and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-residue protein attached to proteins as an intracellular targeting signal).
|
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chains A, B:
E.C.3.4.22.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
Chains A, B:
E.C.3.4.22.69
- Sars coronavirus main proteinase.
|
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
J Med Chem
53:4968-4979
(2010)
|
|
PubMed id:
|
|
|
|
|
| |
|
Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
|
|
A.K.Ghosh,
J.Takayama,
K.V.Rao,
K.Ratia,
R.Chaudhuri,
D.C.Mulhearn,
H.Lee,
D.B.Nichols,
S.Baliji,
S.C.Baker,
M.E.Johnson,
A.D.Mesecar.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The design, synthesis, X-ray crystal structure, molecular modeling, and
biological evaluation of a series of new generation SARS-CoV PLpro inhibitors
are described. A new lead compound 3 (6577871) was identified via
high-throughput screening of a diverse chemical library. Subsequently, we
carried out lead optimization and structure-activity studies to provide a series
of improved inhibitors that show potent PLpro inhibition and antiviral activity
against SARS-CoV infected Vero E6 cells. Interestingly, the (S)-Me inhibitor 15
h (enzyme IC(50) = 0.56 microM; antiviral EC(50) = 9.1 microM) and the
corresponding (R)-Me 15 g (IC(50) = 0.32 microM; antiviral EC(50) = 9.1 microM)
are the most potent compounds in this series, with nearly equivalent enzymatic
inhibition and antiviral activity. A protein-ligand X-ray structure of 15
g-bound SARS-CoV PLpro and a corresponding model of 15 h docked to PLpro provide
intriguing molecular insight into the ligand-binding site interactions.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |
|